top of page
Executive Spotlights

Bicara Therapeutics Announces $108M Series B Financing to Advance Dual-Action Biologics for Cancer

Cambridge, MA, March 6, 2023 (Business Wire) -- Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable anti-tumor response, today announced that it completed an oversubscribed $108 million Series B financing to advance its lead program BCA101 and its pipeline of investigational candidates to treat solid tumor cancers.

Read full article here.

Recent Posts

See All


Life Science Headlines
bottom of page